Poulton Jeffrey V.'s Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Mar 5, 2025
- Accession no.
- 0001735276-25-000031
- Filed
- Mar 5, 2025
- Trade date
- Mar 3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $308.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poulton Jeffrey V.CIK 0001782962 | Officer (EVP, Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | Common Stock | AGrant or awardAcquired | +15,117 | $0.00 | $0 | 49,015 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −350 | $242.37 | −$84,829.5 | 48,665 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −382 | $243.36 | −$92,963.52 | 48,283 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −258 | $244.41 | −$63,057.78 | 48,025 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −189 | $245.26 | −$46,354.14 | 47,836 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −77 | $246.18 | −$18,955.86 | 47,759 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −7 | $247.35 | −$1,731.45 | 47,752 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −1 | $248.36 | −$248.36 | 47,751 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | Common Stock | AGrant or awardAcquired | +9,800 | $0.00 | $0 | 9,800 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.